DALLAS, October 20, 2014 /PRNewswire/ --
ReportsnReports.com adds Gouty Arthritis (Gout) - Pipeline Review, H2 2014 market research report as well as EpiCast Report: Gout - Epidemiology Forecast to 2023 to the pharmaceuticals segment of its online library.
The Gouty Arthritis (Gout) - Pipeline Review, H2 2014 market research report provides comprehensive information on the therapeutic development for Gouty Arthritis (Gout), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gouty Arthritis (Gout) and special features on late-stage and discontinued projects. It features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The EpiCast Report: Gout - Epidemiology Forecast to 2023 market research forecasts an increase in both the diagnosed incident cases and diagnosed prevalent cases of gout in the 6MM, from 1,374,065 diagnosed incident cases in 2013 to 1,649,065 diagnosed incident cases in 2023, at an annual growth rate (AGR) of 2.00%, and 13,750,047 diagnosed prevalent cases in 2013 to 17,625,944 diagnosed prevalent cases in 2023, at an AGR of 2.82%. This forecast is supported by age- and sex-specific data obtained from country-specific estimates from peer reviewed journal articles, in which the study populations were representative of the general population in the respective markets. The researchers and epidemiologists used historical diagnosed incidence and diagnosed prevalence data which were available for Italy and the UK, along with linear regression methods to forecast the age- and sex-specific diagnosed incidence and diagnosed prevalence for Italy and the UK through 2023. The forecast provides the age- and sex-specific diagnosed incident cases and diagnosed prevalent cases of gout in each of the 6MM, with clinically relevant segmentations, which facilitate an in depth understanding of the emerging temporal trends, and informs strategies to improve the management of the disease. Additionally, GlobalData epidemiologists used the same methodology across the 6MM, which allows for a meaningful comparison of the forecast diagnosed incident cases and diagnosed prevalent cases of gout across these markets.
The Gouty Arthritis (Gout) - Pipeline Review, H2 2014 report can be ordered online for following benefits: Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies; Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage; Develop strategic initiatives by understanding the focus areas of leading companies; Identify and understand important and diverse types of therapeutics under development for Gouty Arthritis (Gout); Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline; Devise corrective measures for pipeline projects by understanding Gouty Arthritis (Gout) pipeline depth and focus of Indication therapeutics; Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope; Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Order a copy of this research at http://www.reportsnreports.com/Purchase.aspx?name=311359 .
Scope of the EpiCast Report: Gout - Epidemiology Forecast to 2023 covers an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for gout in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). In addition, this report includes a 10-year epidemiological forecast for the diagnosed incident cases and the diagnosed prevalent cases of gout segmented by sex and age (in five-year age groups beginning at 20 years and ending at =85 years). The diagnosed prevalent cases are then further segmented by the number of cases of gout flares and tophaceous gout. The gout epidemiology report is written and developed by Masters- and PhD-level epidemiologists. The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM. Order a copy of this research at http://www.reportsnreports.com/Purchase.aspx?name=282195 .
Explore more reports on the pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Connect With Us on:
Twitter: https: //twitter.com/marketsreports